CellCentric

CellCentric is a clinical-stage biopharmaceutical company that develops inobrodib, an oral small molecule inhibitor.

Health and bio

Latest funding

$220M Series B+ · May 6, 2026

Led by Venrock Healthcare Capital Partners · Source: fundraisingfox.com

Total raised: $340M across 2 sourced rounds

All 2 rounds ↓

Website: cellcentric.com.

X: @CellCentric · 699 followers.

LinkedIn: cellcentric.

Category: Health and bio.

Sectors: Biotechnology, Life Science, Medical, Therapeutics.

Stage: Series B+.

Based in: Cambridge, United Kingdom.

Total raised: $340M in 2 sourced rounds.

Last round: May 6, 2026 · 193 days ago.

Headcount: 11–50 employees.

On Recent Funding since: Sep 29, 2026.

Signals

X account@CellCentric · created Nov 2, 2009 (17 years old) · 699 followers

Website registeredNov 2, 2003 (23 years old)

About CellCentric

This drug is designed to treat multiple myeloma and other cancers by disrupting the growth of cancer cells. CellCentric aims to develop inobrodib for the benefit of patients and physicians.

TIMELINE · MONEY RAISED

CellCentric | 5677 days from X account to first raise on record

@CellCentric·Raised $340M in 2 sourced rounds·1 signal before the first raise

Money raised, round by round (amounts linked to their source). Pins are dated signals; hover the icons for dates.

Funding rounds

Date	Round	Amount	Lead	Source
May 6, 2026	Series B+	$220M	VVenrock Healthcare Capital Partners	fundraisingfox.com
May 19, 2025	Series B+	$120M	FForbion Capital Partners	thepharmaletter.com

Timeline

November 2, 2009
X account created
November 2, 2003
Website created

Founders and team

AS
Azim Surani Founder
WW
Will West Founder

@whlwest
KC
Karen Clegg Clinical Science Director
TS
Thea Stanway Finance Director & Company Secretary
CE
Celia Economides Chief Financial Officer and Chief Business Officer

Investors

Companies like CellCentric

NNoema PharmaSeries B+ · Nov 2025
SStorm Therapeutics$56M Series B+ · Apr 2026
AAlzheon$100M Series B+ · Apr 2022
AAlpha-9 Oncology$175M Series B+ · Oct 2024
CCity TherapeuticsSeries B+ · Aug 2026
SSagimet BiosciencesSeries B+ · Apr 2026

Other companies backed by Venrock Healthcare Capital Partners

DDevoted Health$366M Series B+ · Mar 2026
AAngitia Bio$130M Series B+ · Feb 2026
TTubulis$360M Series B+ · Oct 2025

Venrock Healthcare Capital Partners portfolio →

Sources and API

Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/cellcentric (get a free API key).